News | December 19, 2024
Cipla launches India's first inhalable insulin ‘Afrezza’
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%
The trademark rights for these brands will be transferred to Lupin by March next year.
Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Subscribe To Our Newsletter & Stay Updated
